IN THE CLAIMS


WHAT IS CLAIMED IS:

1. (CURRENTLY AMENDED) A compound of the formula:

and the pharmaceutically acceptable salts and solvates thereof, wherein:

A is selected from the group consisting of:

- 6 -



wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H;

(3)

wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H;

wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H; and

$$2$$
 R^7
 R^8
 R^9
 R^9
 R^9

B is selected from the group consisting of

$$R^4$$
 R^5
 R^6
 R^6

$$R^{1}$$
 R^{10}
 R^{10}

n is 0 to 6;

p is 1 to 5;

X is O, NH, or S;

Z is 1 to 3;

 R^2 is selected from the group consisting of: hydrogen, OH, -C(O)OH, -SH, -SO₂NR¹³R¹⁴, -NHC(O)R¹³, -NHSO₂NR¹³R¹⁴, -NHSO₂R¹³, -NR¹³R¹⁴, -C(O)NR¹³R¹⁴, -C(O)NHOR¹³, -C(O)NR¹³OH, -S(O₂)OH, -OC(O)R¹³, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group each substituent being independently selected from the group consisting of: R^9

groups, and wherein the heterocyclic acidic functional group is selected from the group consisting of pyrrole, imidazole, triazole, and tetrazole;

each R^3 and R^4 is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, cycloalkyl substituted with 1 to 4 alkyl groups wherein each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups, -OH, -CF₃, -OCF₃, -NO₂, -C(O)R¹³, -C(O)NHR¹⁷, -C(O)NR¹³R¹⁴, -SO_(t)NR¹³R¹⁴, -SO_(t)R¹³, -C(O)NR¹³OR¹⁴, unsubstituted or substituted heteroaryl,

$$\begin{cases} R^{31} & R^{13} \\ P - R^{31} \\ 0 & R^{14} \end{cases}$$
 and
$$\begin{cases} R^{13} \\ N \\ N \\ R^{14} \end{cases}$$

wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R⁹ groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R⁹ groups; or

R³ is and R⁴ taken together with the carbons atoms to which they are bonded to in the phenyl B substituent

$$R^4$$
 R^5
 R^6
 R^3
 R^2
 R^6

form a fused ring of the formula:

$$R^{13}-N = \begin{bmatrix} Z^1 \\ Z^1 \\ 0 \end{bmatrix} = \begin{bmatrix} R^6 \\ R^2 \end{bmatrix}$$
 or
$$R^{13} = \begin{bmatrix} 0 \\ 11 \\ 0 \end{bmatrix} = \begin{bmatrix} R^6 \\ Z^2 \end{bmatrix} = \begin{bmatrix} R^6 \\ R^2 \end{bmatrix}$$

wherein Z^1 or Z^2 is an unsubstituted or substituted saturated heterocyclic ring (preferably a 4 to 7 membered heterocyclic ring), said ring Z^1 or Z^2 optionally containing one additional heteroatom selected from the group consisting of: O, S and NR¹⁸; wherein there are 1 to 3 substituents on said ring Z^1 or Z^2 , and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkyl, cycloalkylalkyl,

heteroaryl, heteroarylalkyl, amino, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -SO_tNR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, -NHC(O)NR¹⁵R¹⁶, -NHC(O)OR¹⁵, halogen, and a heterocycloalkenyl group;

each R^5 and R^6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, -CF₃, -OCF₃, -NO₂, -C(O)R¹³, -C(O)OR¹³, -C(O)NR¹³R¹⁴, -SO_(t)NR¹³R¹⁴, -C(O)NR¹³OR¹⁴, cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R^9 groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R^9 groups;

each R⁷ and R⁸ is independently selected from the group consisting of: H, unsubstituted or substituted aryl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, -CO₂R¹³, -CONR¹³R¹⁴, alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted R⁷ and R⁸ groups, wherein each substitutent is independently selected from the group consisting of:

- a) halogen,
- b) $-CF_3$,
- c) $-COR^{13}$,
- d) $-OR^{13}$,
- e) $-NR^{13}R^{14}$,
- f) $-NO_2$,
- g) –CN,
- h) $-SO_2OR^{13}$,
- i) —Si(alkyl)₃, wherein each alkyl is independently selected,
- j) -Si(aryl)₃, wherein each alkyl is independently selected,
- k) $-(R^{13})_2R^{14}Si$, wherein each R^{13} is independently selected,
- I) $-CO_2R^{13}$,

- m) $-C(O)NR^{13}R^{14}$,
- n) $-SO_2NR^{13}R^{14}$,
- o) $-SO_2R^{13}$,
- p) $-OC(O)R^{13}$,
- q) $-OC(O)NR^{13}R^{14}$,
- r) $-NR^{13}C(O)R^{14}$, and
- s) $-NR^{13}CO_2R^{14}$;

(fluoroalkyl is one non-limiting example of an alkyl group that is substituted with halogen);

R^{8a} is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each R⁹ is independently selected from the group consisting of:

- a) $-R^{13}$,
- b) halogen,
- c) -CF₃,
- d) $-COR^{13}$,
- e) $-OR^{13}$,
- f) $-NR^{13}R^{14}$,
- g) -NO₂,
- h) -CN,
- i) $-SO_2R^{13}$,
- j) -SO₂NR¹³R¹⁴,
- k) $-NR^{13}COR^{14}$,
- I) $-CONR^{13}R^{14}$,
- m) $-NR^{13}CO_2R^{14}$,
- n) $-CO_2R^{13}$,
- 0)

p) alkyl substituted with one or more -OH groups,

- q) alkyl substituted with one or more –NR¹³R¹⁴ group, and
- r) $-N(R^{13})SO_2R^{14}$;

each R^{10} and R^{11} is independently selected from the group consisting of R^{13} , halogen, $-CF_3$, $-OCF_3$, $-NR^{13}R^{14}$, $-NR^{13}C(O)NR^{13}R^{14}$, -OH, $-C(O)OR^{13}$, -SH, $-SO_{(t)}NR^{13}R^{14}$, $-SO_2R^{13}$, $-NHC(O)R^{13}$, $-NHSO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-C(O)NR^{13}OR^{14}$, $-OC(O)R^{13}$ and cyano;

R¹² is selected from the group consisting of: hydrogen, -C(O)OR¹³, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted R¹² groups and each substituent is independently selected from the group consisting of: R⁹ groups;

each R¹³ and R¹⁴ is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted eterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein "heterocyloalkyl" means heterocyclic); wherein there are 1 to 6 substituents on said substituted R¹³ and R¹⁴ groups and each substituent is independently selected from the group consisting of: alkyl, -CF₃, -OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, -N(R⁴⁰)₂, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -S(O)_tNR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, halogen, and -NHC(O)NR¹⁵R¹⁶; or

R¹³ and R¹⁴ taken together with the nitrogen they are attached to in the groups -C(O)NR¹³R¹⁴ and -SO₂NR¹³R¹⁴ form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR¹⁸; wherein there are 1 to 3 substituents on the substituted cyclized R¹³ and R¹⁴ groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -SO₁NR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, -NHC(O)NR¹⁵R¹⁶, -NHC(O)OR¹⁵, halogen, and a heterocycloalkenyl group;

each R¹⁵ and R¹⁶ is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

R¹⁷ is selected from the group consisting of: -SO₂alkyl, -SO₂aryl, -SO₂cycloalkyl, and -SO₂heteroaryl;

R¹⁸ is selected from the group consisting of: H, alkyl, aryl, heteroaryl, -C(O)R¹⁹, -SO₂R¹⁹ and -C(O)NR¹⁹R²⁰;

each R^{19} and R^{20} is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

 R^{30} is selected from the group consisting of: alkyl, cycloalkyl, -CN, -NO₂, or -SO₂ R^{15} provided that R^{15} is not H;

each R³¹ is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted R³¹ groups and each substituent is independently selected from the group consisting of: alkyl, halogen and -CF₃;


each R^{40} is independently selected from the group consisting of: H, alkyl and cycloalkyl;

g is 1 or 2; and t is 0, 1 or 2.


- 2. (CURRENTLY AMENDED) The compound of claim 1 wherein A is selected from the group consisting of:
 - (1) unsubstituted or substituted:

$$R^7$$
 R^8 R_7 R_8 R_7 R_8 R_7 R_8 R_7 R_8 R_7 R_8 R_7 R_8 R_9 R_9

(2) substituted:




3. (ORIGINAL) The compound of Claim 1 wherein substituent A is:




wherein the furan ring is unsubstituted or substituted with 1 or 2 alkyl groups wherein each alkyl group is independently selected, R^7 is selected from the group consisting of: -CF₃, alkyl and cycloalkyl, and R^8 is H.

4. (ORIGINAL) The compound of Claim 1 wherein substituent A is:



wherein the furan ring is substituted with 1 or 2 alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl, R⁷ is selected from the group consisting of: ethyl, isopropyl and t-butyl, and R⁸ is H.

5. (CURRENTLY AMENDED) The compound of Claim 1 wherein A is selected from the group consisting of:



6. (ORIGINAL) The compound of claim 1 wherein A is selected from the group consisting of:

7. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:

8. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

9. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

10. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

11. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

12. (ORIGINAL) The compound of Claim 1 wherein B is

13. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is -OH.

14. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is-OH, and R¹³ and R¹⁴ are independently selected from the group consisting of H and alkyl.

15. (ORIGINAL) The compound of Claim 1 wherein B is

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{2}$$

- 16. (ORIGINAL) The compound of Claim 15 wherein R¹¹ is H.
- 17. (ORIGINAL) The compound of Claim 16 wherein R² is -OH.
- 18. (ORIGINAL) The compound of Claim 17 wherein R³ is -C(O)NR¹³R¹⁴.
- 19. (ORIGINAL) The compound of Claim 17 wherein R³ is -S(O)_tNR¹³R¹⁴.
- 20. (ORIGINAL) The compound of Claim 1 wherein B is:

$$\mathbb{R}^{3}$$
 \mathbb{R}^{2}

wherein R² is –OH, R³ is –C(O)NR¹³R¹⁴, R¹¹ is H or methyl, and R¹³ and R¹⁴ are independently selected from the group consisting of: H, alkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heteroaryl and substituted heteroaryl.

21. (ORIGINAL) The compound of Claim 1 wherein B is:

$$\mathbb{R}^{3}$$
 \mathbb{R}^{2}

wherein R^2 is -OH, R^3 is $-S(O)_tNR^{13}R^{14}$, R^{11} is H or methyl, and R^{13} and R^{14} are independently selected from the group consisting of H, alkyl, unsubstituted cycloalkyl and substituted cycloalkyl.

22. (ORIGINAL) The compound of Claim 1 wherein B is:

- 23. (ORIGINAL) The compound of Claim 22 in R¹¹ is H.
- 24. (ORIGINAL) The compound of Claim 23 wherein R² is -OH.
- 25. (ORIGINAL) The compound of Claim 24 wherein R³ is -C(O)NR¹³R¹⁴.
- 26. (ORIGINAL) The compound of Claim 24 wherein R³ is -S(O)_tNR¹³R¹⁴.
- 27. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is –OH, R³ is –C(O)NR¹³R¹⁴, R¹¹ is H, and R¹³ and R¹⁴ are independently selected from the group consisting of: H, alkyl, unsubstituted heteroaryl and substituted heteroaryl.

28. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R^2 is -OH, R^3 is $-S(O)_tNR^{13}R^{14}$, R^{11} is H, and R^{13} and R^{14} are independently selected from the group consisting of H and alkyl.

- 29. (CURRENTLY AMENDED) The compound of Claim 1 wherein:
- (1) substituent A in formula IA is selected from the group consisting of:

wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and –CF₃; R⁷ is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and

(b)

wherein the above ring is substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and –CF₃; R⁷ is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and

wherein R⁷ is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and R^{8a} is as defined in Claim 1:

(2) substituent B in formula IA is selected from the group consisting of:

$$R^{13}$$
 R^{14}
 R^{14}
 R^{15}
 R^{15}

wherein:

R² is selected from the group consisting of: H, OH, -NHC(O)R¹³ and -NHSO₂R¹³;

 R^3 is selected from the group consisting of: $-C(O)NR^{13}R^{14}$ $-SO_2NR^{13}R^{14}$, $-NO_2$, cyano, and $-SO_2R^{13}$;

 ${\sf R}^4$ is selected from the group consisting of: H, -NO2, cyano, alkyl, halogen and -CF3;

R⁵ is selected from the group consisting of: H, -CF₃, -NO₂, halogen and cyano;

R⁶ is selected from the group consisting of: H, alkyl and -CF₃;

R¹¹ is selected from the group consisting of: H, halogen and alkyl; and each R¹³ and R¹⁴ is independently selected from the group consisting of: H, unsubstituted alkyl.

30. (ORIGINAL) The compound of Claim 1 wherein:

(1) substituent A in formula IA is selected from the group consisting of:

(2) substituent B in formula IA is selected from the group consisting

of:

$$R^{13}$$
 R^{14}
 R^{14}
 R^{14}
 R^{14}
 R^{15}
 R^{15}

wherein:

R² is -OH;

R³ is selected from the group consisting of: -SO₂NR¹³R¹⁴ and -CONR¹³R¹⁴;

R⁴ is selected form the group consisting of: H, Br, -CH₃, ethyl and -CF₃;


R⁵ is selected from the group consisting of: H and cyano;

 R^6 is selected from the group consisting of: H, -CH₃ and -CF₃;

R¹¹ is H; and


 ${\sf R}^{13}$ and ${\sf R}^{14}$ are independently selected from the group consisting of H and methyl.

31. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:



and substituent B is selected from the group consisting of:

32. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:



and substituent B is selected from the group consisting of:

- 33. (ORIGINAL) The compound of Claim 1 wherein g is 1.
- 34. (ORIGINAL) The compound of Claim 1 wherein g is 2.

- 35. (ORIGINAL) The compound of Claim 31 wherein g is 1.
- 36. (ORIGINAL) The compound of Claim 32 wherein g is 2.
- 37. (CURRENTLY AMENDED) A <u>sodium</u>, <u>potassium</u>, <u>calcium</u>, <u>aluminum</u>, <u>gold</u>, <u>silver</u>, <u>N-methylglucamine</u>, <u>hydrochloric</u>, <u>sulfuric</u>, <u>phosphoric</u>, <u>acetic</u>, <u>citric</u>, <u>oxalic</u>, <u>malonic</u>, <u>salicylic</u>, <u>malic</u>, <u>fumaric</u>, <u>succinic</u>, <u>ascorbic</u>, <u>maleic</u>, <u>or</u> <u>methanesulfonic</u> <u>pharmaceutically acceptable</u> salt of a compound of Claim 1.
 - 38. (ORIGINAL) A sodium salt of a compound of Claim 1.
 - 39. (ORIGINAL) A calcium salt of a compound of Claim 1.
- 40. (CURRENTLY AMENDED) The \underline{A} compound of Claim 1 selected from the group consisting of:

(a12)

он

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.

41. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 selected from the group consisting of:

(a14)

(a13)

(a36)

(a35)

$$(a47)$$

$$(a48)$$

$$(a49)$$

$$(a50)$$

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.

(a51)

(a52)

42. (CURRENTLY AMENDED) The compound of Claim 4 41 selected from the group consisting of compounds of the formula:

$$\begin{array}{c} O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ \end{array}$$

$$\begin{array}{c} O \\ \end{array}$$

$$\begin{array}{c} O \\ O \\ \end{array}$$

$$\begin{array}{c} O$$

(a25) (a26)

(a48)

(a47)

the pharmaceutically acceptable salts thereof, and the pharmaceutically acceptable solvates thereof.

43. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

45. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

46. (ORIGINAL) The compound of Claim 42 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

47. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

49. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

50. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

51. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

53. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

54. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

55. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

57. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

58. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

59. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

61. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

62. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

63. (ORIGINAL) The compound of Claim 41 having the formula:

64. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

65. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

66. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

67. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

- 68. Canceled (without prejudice).
- 69. Canceled (without prejudice).
- 70. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.
- 71. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.
- 72. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.
- 73. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.
 - 74. Canceled (without prejudice).

- 75. Canceled (without prejudice).
- 76. Canceled (without prejudice).
- 77. Canceled (without prejudice).
- 78. Canceled (without prejudice).
- 79. Canceled (without prejudice).
- 80. Canceled (without prejudice).
- 81. Canceled (without prejudice).
- 82. Canceled (without prejudice).
- 83. Canceled (without prejudice).
- 84. Canceled (without prejudice).
- 85. Canceled (without prejudice).
- 86. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.
- 87. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group

- 60 consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, β -methasone, β interferon, glatiramer acetate, prednisone, etonercept, and infliximab. 88. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof. 89. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of COX-2 inhibitors, COX inhibitors, immunosuppressives, steroids, PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, and other classes of compounds indicated for the treatment of rheumatoid arthritis. 90. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of thrombolitics, antiplatelet agents, antagonists, anticoagulants, and other compounds indicated for the treatment of rheumatoid arthritis. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury 91. in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase, abciximab, eftiifbatide, and heparin. (ORIGINAL) A method of treating psoriasis in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective

amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives, steroids, and anti-TNF- α compounds.

- 93. (ORIGINAL) A method of treating COPD in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof.
 - 94. Canceled (without prejudice).
 - 95. Canceled (without prejudice).
 - 96. Canceled (without prejudice).
 - 97. Canceled (without prejudice).
 - 98. Canceled (without prejudice).
 - 99. Canceled (without prejudice).
 - 100. Canceled (without prejudice).
 - 101. Canceled (without prejudice).
 - 102. Canceled (without prejudice).
 - 103. Canceled (without prejudice).
 - 104. Canceled (without prejudice).
 - 105. Canceled (without prejudice).

- 106. Canceled (without prejudice).
- 107. Canceled (without prejudice).
- 108. Canceled (without prejudice).
- 109. Canceled (without prejudice).
- 110. Canceled (without prejudice).
- 111. Canceled (without prejudice).
- 112. (ORGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.
- 113. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, β -methasone, β -interferon, glatiramer acetate, prednisone, etonercept, and infliximab.
- 114. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof.
- 115. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically

- 121. Canceled (without prejudice).
- 122. Canceled (without prejudice).
- 123. Canceled (without prejudice).
- 124. Canceled (without prejudice).
- 125. Canceled (without prejudice).
- 126. Canceled (without prejudice)
- 127. Canceled (without prejudice)
- 128. Canceled (without prejudice).
- 129. Canceled (without prejudice).
- 130. Canceled (without prejudice)
- 131. Canceled (without prejudice)s.
- 132. (NEW) A compound selected from the group consisting of:

(Example 1)

Ex.	
2	
	N OH H H
3	
	OH H H
4	O, O N, S, N
	OH H H
5	
	O OH H H
6	Q, O N, S, N
;	O OH H H
7	
	N O OH H
8	O S O
	N O OH H H
	U Un

9	0,0
	O OH H H
10	O, O
	O OH H H
11	O S O
	O OH H H
12	
	N N Ph
	о он п н о в
13	O S O N S N
	O OH H H
14	O O N S N
	N OH H
4.5	
15.	
	I \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	о он н н <u>г</u>
L	

16	ON SIN NO H H H CI
17	
18	
19	ON ON CF3 N H H
20	ON ON OCF3 N H H OH OH
21	O O O O O O O O O O O O O O O O O O O

22	ON N H H OH
23	O S H H OH OH
24	ON S N N N N N N N N N N N N N N N N N N
25	ON NO H
26	
27	ON NON NON NON NON NON NON NON NON NON

28	O O
20	N, S, N
	H H H
	N OH
29	0,0
	N N
	N N
	\ \ \ H H H
	ОН
30	O O O
	N N
	N N S
	N OH H H
31	O O
:	N N
	H H H
	OH OH
32	0,0
	_
	N
	OH H
33	0,0
	N, N
	N N S
	OH H H
	/ %

	0 0
34	N N N
	N N S
	N OH H H
	ľÖ
35	0, 0 N S N
	N N N
	OH H H
	, o
36	N S N
	N N
	N N S
	N H H
	O OH
37	0,0
	N N CF ₃
	N N N
	\ \ \ H H \ \ \ \ \ \
	O OH
38	0,50
	N N
	N N
	OH H H
39	
33	O_2N N N
	N N Ph OH H H
40	0,0
	NC NSN
	N N Ph
	OH H H

41	O, O S.
	N N
	N Ph
	он н
42	
	SNN
	—N N N Ph HO H H
43	0 0 0
	HO N N
	N N Ph
	он н
44	
	N N
	NC N N Ph
45	O O
	F N S N
	N N Ph
	OH ''
46	
÷	O N Ph
47	
	NH ₂ OH H
48	0, 0
	0.05 NN
	O O S N N Ph
	∖HÓ H H
49	
	N N N
	N N Ph
L	ОН Н Н

50	O, O
7	N N CF ₃
	N N O
	ОН
51	O O N S N
	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	NC OH H
52	O, O
	N S N
	NC OH H
53	0,,0
	NC OH H
54	0, 0
	O_2N
	OH N N
55	O O
	N N
	Br N N O
	N OH
56	0,0
	N N
	OH H H

57	O S N N N H H
	ЮH
	0 0
58	O O N S N
	Br—NNN
	H H
	O OH
59	0,0
	N N
	CI
	H ₂ N-S OH
60	0,0
	N N
	NO OH H
61	0,0
	N N
	H H
	O OH
62	0,0
	N N N
	OH \ / /
63	0 0
	N N
	N H H
	\ \"\"\ OH \\ \ \
	HO ₂ Citi

GA.	0, ,0
64	N, N
	H H
[NC OH
65	O O
	N N
	HO H H
66	
	Br N N O
	N OH
67	O O N N
	H H S
	N- OH
	0, 0
68	N N
	N N
	N OH H H
69	0,0
	N N
	OH H H
	<u> </u>

	0, ,0
70	O O N S N
	N N
	OH H H
71	0, 0 N S N
	O_2N
	N N
	OH H
72	
	O OH H H O
100	Q, O N, S, N
	N ^S N
	OH H H
101	O, o
	N'S'N
	N N N N
	OH H H
103	<u> </u>
	O OH H H
104	
	N N N
	о он н н н н н н н н н н н н н н н н н
105	Q, Q N, S, N
	N.S.N.
	O OH H H

106	9,,0
	$ $ $\langle N \rangle \langle N \rangle $
107	0 011
108	0 011 11
100	
	N N N S
109	O OH H H
109	O OH H H O
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
110	
110	
111	Ö ÓH H H L// Q,O
'''	N ^S N /
	N N N N N N N N N N N N N N N N N N N
112	Ö ÖH H H L
112	N.S.N
	N N N TO N
113	Ö ÖH H H L
113	NS N
	N N N N
114	Ö ÓH H H 🖳
114	
	Ö ОНН Н 🖤

115	ON SIN NO
116	ON NO N
117	O, O N, S, N N, N, H O, O N, H O, N O, N O, N O, N O, N O, N O, N O, N
118	ON NO NO CI
119	O, O N, S, N N, N N
120	ON ON NO N
121	
122	ON ON SIN DE CONTRACTOR OF THE

123	N S N N N N N N N N N N N N N N N N N N
124	N N N N N N N N N N N N N N N N N N N
125	
126	ON NO N
127	
128	Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q
129	O O O N S N D O O O O O O O O O O O O O O O O O O
130	

131	O OH H H
132	OH OH
134	
135	O S N N N N N N N N N N N N N N N N N N
136	
137	
138	
139	N S N N CI

140	N S N N CI
141	NS N N N N N N N N N N N N N N N N N N
142	O O O O O O O O O O O O O O O O O O O
143	NS N N N N N N N N N N N N N N N N N N
144	NS N N N N N N N N N N N N N N N N N N
145	N S N N N N N N N N N N N N N N N N N N
146	O O O N N N O O O O O O O O O O O O O O
147	N S N N N N N N N N N N N N N N N N N N
148	N N N N N N N N N N N N N N N N N N N

149	
150	N OH H H
151	O, O N, N CF ₃ N, N CF ₃ N, N N N, N N N N, N N N N N
152	ON NO CF3
153	S N N H
154	S N N N N N N N N N N N N N N N N N N N
155	S N N N N N N N N N N N N N N N N N N N
156	S N N N N N N N N N N N N N N N N N N N
157	S N N N N N N N N N N N N N N N N N N N

,	
158	S N N N N N N N N N N N N N N N N N N N
159	S N N N N N N N N N N N N N N N N N N N
160	ON SON NO N
161	N-S OH OCI
162	ONS N N S N H H
163	N-S OH OH
164	ONS N N N H H

165	
166	
167	O S HO HO
168	
169	
170	ON SIN NO
171	Br N N OCI

•	
172	Br N N O O O O O O O O O O O O O O O O O
173	Br N H H OH OH
174	ON NON HOO
175	Br N N N OH OH
176	Br N N N N N N N N N N N N N N N N N N N
177	H S N N N N N N N N N N N N N N N N N N
178	Br N N N N N N N N N N N N N N N N N N N

179	
180	
181	O Z H H O CI
182	O N N H H OH OH
183	ON NON NON NON NON NON NON NON NON NON
184	ON N N OCI
185	O, O N S N H H

186	ON SIN NOH NOH NOH NOH NOH NOH NOH NOH NOH NO
187	ON NO NO CI
188	O S N N N N N N N N N N N N N N N N N N

Ex.	
201.1	
201.2	0=00 2 2 H 0 H 0 H
201.3	0=0 H Z H OH OH
201.4	OH N N N N N N N N N N N N N N N N N N N

201.5	O=S N N OH OH
201.6	
201.7	OIS N H H
201.8	O=S N N H OH

201.9	O=S N N N N N N N N N N N N N N N N N N N
202	
203	
204	O S N N O O O O O O O O O O O O O O O O
205	
206	

207	
	N OH OH
208	0 = S N N
	Br—N N—M
209	O S
	Br N N N N N N N N N N N N N N N N N N N
	он н
210	0
	Br N N
	Br N N OH
211	0=8
	Br N N O
	ОН Н Н
212	O
	Br—NN—
	он н

213	0
	N ^S N
	Br N N O
	N OH
214	O
	N N
	CI——N N—N—N—S OH
	N-S OH
215	N. N
	CI
	N S OH H H
216	O S
	CINNSN
	N S OH H H
217	O S.
	CINNN
	N S N N N N N N N N N N N N N N N N N N
218	O S
	CI
	N S OH H H
219	0 S
	CI
	N S N N N O O O O O O O O O O O O O O O
	CI

220	O
	N S N
	N-S
	N-S OH
221	O = 0
	N N
	N N
	OH HH
222	O S
	N N
	N S OH H H
	O OH H H
223	O S
	N-S OH H H
224	
227	
	OH H H
225	O S
	N S N N N O
226	O
	/ s- N S N
	O HO H H

227	0 S
	S N N N N N N N N N N N N N N N N N N N
228	0=0
	S N N N N N N N N N N N N N N N N N N N
229	
230	
	O HO H H
231	
232	
233	

234	S N N N N N N N N N N N N N N N N N N N
235	
236	
237	
238	
239	O II S N N N N N N N N N N N N N N N N N
240	Br N N N OH OH

	0
241	₩ S.
	N N
	Br N N
	\ H H _/
	OH Br
241.1	O II
•	N-S N N
044.0	0 0 0 н п
241.2	 S
	CINN
	N S OH H H
	0 0 4 Br
241.3	O S
	N N N
	N S OH H H
241.4	
	N S N N N N N N N N N N N N N N N N N N
0.40	
242	0=5,2
	N N N H H
243	О НО П 11 О ,S.
240	,
	N ST
	O S N N N H H Br
244	HO Br' O
	S N N N
	O HO H H

245	S N N N N N N N N N N N N N N N N N N N
246	
248	
249	O=S Z Z N H H OH
251	

252	
254	O S Z N N H HO H H
255	D = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 = 0 =
256	OH OH OH
257	

258	
259	
260	
262	
263	

264	0
	F ₃ C N N N N N N N N N N N N N N N N N N N
265	F ₃ C O S N S N S N S N S N S N S N S N S N S
266	
267	
268	
269	F ₃ C N N N N N N H

270	
271	S S N S N S N S N S N S N S N S N S N S
272	F ₃ C O S N F O O O O O O O O O O O O O O O O O O
273	
274	
275	F ₃ C N S N O O O H H

276	CI N S OH H H
277	CI N S OH H
278	
279	CI NS NH NH NH NH
280	

281	
282	
283	
284	
285	
286	O S N T N N H

287	
289	
291	
292	0=\(\sigma_{\sigma}\) \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \
293	
294	

295	
296	
297	
298	OH N N N N N N N N N N N N N N N N N N N
299	Br N N N N N N N N N N N N N N N N N N N

300	Br N N N N H
301	F_3C N
302	F_3C $O = S$ $N \rightarrow N$ $O = S$ $N \rightarrow N$ $O \rightarrow N$
303	F ₃ C N N N N N N N N N N N N N N N N N N N
304	F ₃ C N N N N N N H

305	
306	
307	
308	
309	
310	

311	
312	
313	Br N N N N N N N N N N N N N N N N N N N
314	
315	S N S N S N S N S N S N S N S N S N S N
316	

317	
318	
319	
320	N S OH H H
321	

322	
323	
324	
325	H S N N H
326	H-N-S-N-H-N-H-N-H-N-H-N-H-N-H-N-H-N-H-N-

327	H, S, N,
328	
329	-N
	H S N N N N N N N N N N N N N N N N N N
330	O S N H N H
331	

332	
333	
334	
335	
336	

337	H-N-SOOH N-H
338	
339	
340	
341	

342	
343	
344	
345	

346	
347	
348	
349	F ₃ C N N N N N OH OH

350	
351	
352	
353	O=S, N N N H OH OH

354	OII S N F F F N N H H OH
355	
356	
357	OH NOH H H

358	
359	OH S N H H
360	
361	F ₃ C N N N N OH OH

362	F ₃ C N N N N N N N N N N N N N N N N N N N
363	HO _{II} , NOH
364	
365	

366	O=S NOH HONOH HONOH
367	
368	
369	OII S N N N N N N N N N N N N N N N N N N N

370	OIIS N N H H OH OH
371	0=S, Z, M, OH OH OH
372	OH S OH OH
373	OH N N S

374	F_3C N
375	OIS Z H H OH OH
376	
377	OII S H H OH OH

378	OIIS NOT
379	OIIS N N OH
380	
381	

382	F ₃ C N N N N OH OH
383	Br N N N OH H H
384	OES Z H H OH OH
385	OII S N-S OH

386	
387	
388	
389	

390	
391	CI H_2N OH H H H
392	CI H_2N OH OH OH OH OH OH OH OH
393	CI N

394	0 S
	CI N N N H H H
2001	
	OH NMe ₂ Ph
2002	N S N
	OH NMe ₂
2003	
	O OH H H
2004	ON O
	$O = \begin{array}{cccc} & & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & \\ & & \\ & \\ & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ $
2005	N S N Y
	O=OH NMe ₂

2006	
	F ₃ C-NNN NO
	O≕(OH NMe ₂
2007	O O S
	N N N
	о ОН
	· ,
2008	NMe ₂
	NMe ₂
2009	ONS N
	OMa
	H H Olvie
	O=\ OH NMe ₂
2010	O, O
	N N
	O=OH NMe ₂
2011	O O V
	N N
	H H
	O= OH OMe
2012	NMe ₂
2012	N S N
	N
	OH OH
	NMe ₂
	OMe

2013	N S N
	F_3C O
2014	NMe ₂
2011	\sim N, N, \sim
	N
	О⇒ОН
	NMe ₂
2015	O S N
	H H H
	O⇒ OH NMe ₂
2016	O O N S N
	OH N N
	NMe ₂ CONMe ₂
2017	
	O → OH
2018	NMe ₂
2018	- N N
	NH N
	OH NMe ₂
	NMe ₂ CF ₃ CO ₂ H
2019	$C\Gamma_3CO_2\Pi$
	О ОН Н
L	L

2020	ON N HN OH OH
2021	
2022	ON HIN OH OH
2023	ON N N H OME OME
2024	
2025	O O O O O O O O O O O O O O O O O O O
2026	

2027	O O N N N N N N N N N N N N N N N N N N
2028	ON ON NON NON NON NON NON NON NON NON N
2029	ON NHN HN OH
2031	ON NON HN ON OH
2032	
2033	
2034	OH NH NH

0005	
2035	
2036	O, O S'
	N S O OH H H
2037	O O
	Br N S N
	N S OH H H
2038	0,0 S
	O OH H H
2039	0, 0
	Br N N
	OH H H
2040	0,0
	O OH N N
2041	O, O
	N N N N N N N N N N N N N N N N N N N
2042	O S O
	O OH H H
	• • • • • • • • • • • • • • • • • • • •

2043	O O OH H H
2044	
2045	HO N N N N N N N N N N N N N N N N N N N
2046	
2047	Br N N N N N N N N N N N N N N N N N N N
2049	
2050	ON NON NON NON NON NON NON NON NON NON

2051	N.S.N.
	O H N N
	OH H
	ОН
	0 0
2052	
	N N V
	O H HN TO
	OH OH
	N
2053	0,0
	N N
	O H HN O
	N OH
2054	0, 0 N-S
	N HN TO
	N OH
	ОН
2055	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	N N N
	$O \longrightarrow H HN \longrightarrow O$
	N OH
	ОН
2056	0,0
	NSN V
	N N
	OH H H
	N OH

2055	0. 0
2057	N.S.
	Br N N
	N N O
) ОН // <i>></i> —— /
	_N
2058	
	N N
	N N
	OH H
	_N
2059	0,0
	N N
	N HN
	N OH H
	`N´
2060	O O
	N N V
	N N
	OH H H TO
	N OH
	N
	N
2062	O O N S N
	O N N
	Y Y N HN \
	N OH T
	ОН
2063	
	N N K
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	OH H H
	N V

	0 0
2064	
	N OH HN
	ООН
2065	
	S
	ON NOTIFIED TO THE PARTY OF THE
	О ОН "
2066	
	N S N S N
	N N N N N N N N N N N N N N N N N N N
	но н н
0007	
2067	
	N S H ₃ C CH ₃ CH ₃
	N S N CH ₃
2068	0,0
	-N S N Y
	HO H H

2069	
2070	N S N N N N N N N N N N N N N N N N N N
2071	OO
2072	OO NS N NO N N N N N N N N N N N N N N N
2073	OO N N N N OO OH H H H
2074	OO
2075	OO

2076	0,,0
	N S N
	N- OH T T
2077	O, O
	N N V
	N N
	\. \>\ H H H \-0
	N OH
2078	0, 0
2076	N N V
]	
	N N
	N-W OH H H
2079	0,,0
	N, S, N
	H H H >-0
	OH CI
2080	O, O N, S, N, V
	N, N
	H H H >-Q
	OH
	Br

2081	O O
	N N
,	
	OH OH
0000	0 0
2082	
	, / N N
	N-OH H H
2083	O, O
	N N-
	H H
	/_\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
2084	
	NON Y
	N N-
	OH H H
2085	0,,0
2003	N N
	N N N
	N- OH " " _ DO
	0 1 F
L	<u> </u>

2086	0, 0 N, N N, N N, N OH H H
2087	N N N F F F F
2088	0, 0 N, S, N N N N N H H H
2089	
2090	0,0 N,S,N N,N,N,N,N,N,N,N,N,N,N,N,N,N,N,N,N

2091	O, ,O
	N, N
	N N
	N OH H H
2092	O, O
	N N Y
	N N-
	_N(ОН Н Н ()-CI
	CI
2093	O, O N N \ /
	H H
	OH S
2094	0,0
	N N
	N-(OH H H
2095	O, O N S N \ /
	NON X
	N-OH H H
	ò-{
L	<u> </u>

2096	0, 0
	N, N
	N- OH H H
	OH (_)
	\searrow
2097	Br N N
	Br N'S N
	N N
	SOOH HH
2098	O, O N S N \ /
	N N
	S OH H H
2099	
	N. N.
	H H H
	S OH
0100	0.0
2100	N.S.N.
	H H H
	O'S OH
L.,	U

2101	
	Br N N
	N-(OH ., ., ()
	0 0
2102	N.S.N.
	N.S.N
	N-S OH H H
	O OH
2103	O, O
	N, S, N \
	Br-N N-
	N-OH H H
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
2104	O, O
	N N-
	N- OH H H (
	0 F
2105	O, O N.S.N \/
	N N
	N-O OH H H

2106	O, O
	N N V
	N N
	N-W OH H H
2107	O, ,O
	N ^S N F
	N N
	N- OH " "
2108	O, O N ^S N F, F
	NON F
	N N
	N-OHHH
2109	0, 0 , S
	N N N
	N- OH " "
2110	0, ,0
	N S N
	N N
	0/

2111	O,_,O
	N,S,N \
	N N
	N OH C
	N-/
2112	O, ,O , ,S, ,
	N,S,N Y
	$N \sim N \sim 1$
	N-MOH H
) ö " \
	and
2113	O, O N, S, N \/
	N, N
	, N N
	N-OH H H